Literature DB >> 14063327

CHRONIC MYELOID LEUKAEMIA WITH LYMPHOSARCOMA.

J S HOWELL, A G WHITFIELD.   

Abstract

The clinical and pathological features of two patients with chronic myeloid leukaemia who died from lymphosarcoma are described. Both had been treated with busulphan which, at the time of development of lymphosarcoma and at death, appeared to be controlling the leukaemia satisfactorily.

Entities:  

Keywords:  LEUKEMIA, MYELOCYTIC; LYMPHOSARCOMA; PATHOLOGY

Mesh：

Year:  1963        PMID： 14063327      PMCID： PMC480603          DOI： 10.1136/jcp.16.5.432

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  6 in total

1.  Recticulum cell sarcoma terminating in acute leukemia.

Authors:  J L ZEFFREN; J E ULTMANN
Journal:  Blood       Date:  1960-02       Impact factor: 22.113

2.  [On the problem of the transition of chronic myeloleukemia into reticulosarcomatosis].

Authors:  T A BELOLIPETSKAIA; I I GETS
Journal:  Arkh Patol       Date:  1960

3.  Lymphosarcoma with myeloid leukemia: case report.

Authors:  H V SARDESAI; K C BHATIA
Journal:  Indian J Med Sci       Date:  1959-10

4.  A case of myeloid reticulosis.

Authors:  D E WILCKEN
Journal:  Med J Aust       Date:  1957-02-16       Impact factor: 7.738

5.  Leukemia or lymphoma and coexistent primary malignant lesions: a review of the literature and a study of 120 cases.

Authors:  C G MOERTEL; A B HAGEDORN
Journal:  Blood       Date:  1957-09       Impact factor: 22.113

6.  The development of acute myelogenous leukemia in a patient with reticulum cell lymphoma.

Authors:  E BEUTLER
Journal:  Ann Intern Med       Date:  1954-06       Impact factor: 25.391
  6 in total
  2 in total

1.  Proceedings: The effect of immunosuppression on cancer.

Authors:  I Penn; T E Starzl
Journal:  Proc Natl Cancer Conf       Date:  1972

2.  Lymphosarcoma during the course of myeloid leukaemia.

Authors:  J J Taylor; D W Evans
Journal:  Postgrad Med J       Date:  1968-07       Impact factor: 2.401
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.